Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B John

Showing results (31-40 of 612) with videos related to

Pageof 62
Sort By:
Journal of the American Heart Association|August 7, 2023
Reframing the Paradigm for Assessing Optimal Test Selection When Suspecting Chronic Coronary DiseaseG B John Mancini
General and Comparative Endocrinology|January 1, 1990
Thyroid regulation of resting metabolic rate and intermediary metabolic enzymes in a lizard (Sceloporus occidentalis)H B John-Alder
The American Journal of Physiology|May 1, 1983
Effects of thyroxine supplementation on metabolic rate and aerobic capacity in a lizardH B John-Alder
European Journal of Preventive Cardiology|May 14, 2014
The concepts of 'proportions of symptoms nonpharmacological' and unmitigated failureG B John Mancini
The Canadian Journal of Cardiology|January 17, 2015
The fire within psoriatic patients: overlap between inflammatory and cardiovascular diseasesG B John Mancini
The British Journal of Theatre Nursing : Natnews : the Official Journal of the National Association of Theatre Nurses|November 18, 1997
The design and introduction of videos and leafletsJ White, B John
The Canadian Journal of Cardiology|July 11, 2025
Begin With The End In Mind: What 75-Year Follow-Up of Young, Healthy Individuals Can Teach Us About Prevention of Cardiovascular DiseaseG B John Mancini
The Canadian Journal of Cardiology|January 9, 2003
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammationG B John Mancini
Chromosoma|December 29, 1975
The cytogenetic structure of Tasmanian populations of Phaulacridium vittatumB John, M Freeman
The Canadian Journal of Cardiology|May 27, 2005
The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockersG B John Mancini
Pageof 62

Showing results (31-40 of 612) with videos related to

Sort By:
Pageof 62
Journal of the American Heart Association|August 7, 2023
Reframing the Paradigm for Assessing Optimal Test Selection When Suspecting Chronic Coronary DiseaseG B John Mancini
General and Comparative Endocrinology|January 1, 1990
Thyroid regulation of resting metabolic rate and intermediary metabolic enzymes in a lizard (Sceloporus occidentalis)H B John-Alder
The American Journal of Physiology|May 1, 1983
Effects of thyroxine supplementation on metabolic rate and aerobic capacity in a lizardH B John-Alder
European Journal of Preventive Cardiology|May 14, 2014
The concepts of 'proportions of symptoms nonpharmacological' and unmitigated failureG B John Mancini
The Canadian Journal of Cardiology|January 17, 2015
The fire within psoriatic patients: overlap between inflammatory and cardiovascular diseasesG B John Mancini
The British Journal of Theatre Nursing : Natnews : the Official Journal of the National Association of Theatre Nurses|November 18, 1997
The design and introduction of videos and leafletsJ White, B John
The Canadian Journal of Cardiology|July 11, 2025
Begin With The End In Mind: What 75-Year Follow-Up of Young, Healthy Individuals Can Teach Us About Prevention of Cardiovascular DiseaseG B John Mancini
The Canadian Journal of Cardiology|January 9, 2003
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammationG B John Mancini
Chromosoma|December 29, 1975
The cytogenetic structure of Tasmanian populations of Phaulacridium vittatumB John, M Freeman
The Canadian Journal of Cardiology|May 27, 2005
The 'double dip' hypothesis: simultaneous prevention of cardiovascular and pulmonary morbidity and mortality using angiotensin II type 1 receptor blockersG B John Mancini
Pageof 62